Aug 2026· Journal of Applied Microbiology· Vol 137· 0 citations
Medicine
TL;DR
Findings support integrating phage therapy with conventional antibiotics as a promising strategy for UTI management by confirming that phages remained effective in physiologically relevant conditions, despite reduced antibiotic efficacy in urine.
Abstract
Aims
To evaluate the efficacy of bacteriophage-antibiotic combination therapy against major urinary tract infection (UTI) pathogens and determine whether combining phages with ciprofloxacin enhances bacterial killing, delays resistance emergence, and improves treatment performance under physiologically relevant conditions.
Materials And Methods
Five clinically relevant UTI pathogens were tested: Escherichia coli (UPEC), Enterococcus faecalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis. Phages from a commercially available cocktail were screened and supplemented with a lab-isolated phage to improve E. coli coverage. In vitro assays evaluated bacterial inactivation using phages alone and in combination with ciprofloxacin at varying concentrations, including sub-MIC levels. Resistance emergence and associated fitness costs were assessed. Ex vivo efficacy was further tested using filtered human urine to simulate physiologically relevant conditions.
Results
Phage-antibiotic combinations significantly enhanced bacterial inactivation across all tested species compared to monotherapies, including at sub-MIC ciprofloxacin concentrations. Combination treatments delayed resistance development and imposed fitness costs on resistant E. coli mutants. Ex vivo urine assays confirmed that phages remained effective in physiologically relevant conditions, particularly in combination regimens, despite reduced antibiotic efficacy in urine.
Conclusions
Phage-antibiotic combination therapy improves bacterial killing, suppresses resistance emergence, and remains effective in urine-based models. These findings support integrating phage therapy with conventional antibiotics as a promising strategy for UTI management.
Antimicrobial resistance poses a major challenge to veterinary and human medicine, particularly in the context of difficult-to-treat infections caused by multidrug-resistant (MDR) bacteria. Pseudomonas aeruginosa, a WHO priority pathogen, is known for its resistance profile and ability to form biofilms. As an alternati...
Margarida C. Gomes, Patricia Boto, M. Oliveira et al.· Pathogens· 0 citations
Treating bacterial infections, such as urinary tract infection (UTI), with antibiotics does not always resolve the infection and often results in subsequent re-infection. Treatment failure can be driven by bacterial mechanisms of resistance, tolerance or persistence, collectively known as the antibiotic non-response. A...
Ariana Costas, Bill Söderström, Molly A. Ingersoll· Nature reviews. Urology· 0 citations
Biofilm formation by uropathogenic Escherichia coli contributes to antibiotic resistance and the persistence of urinary tract infections. Whether biofilm formation is an intrinsic characteristic of UPEC or an adaptive response to antibiotic stress remains unclear, as does whether such adaptation is a generalized respon...
N. Srivastava, Sheetal Verma, Meenu Singh et al.· Bacteria· 0 citations
Pseudomonas aeruginosa is an opportunistic Gram-negative bacillus responsible for several infectious conditions, including ventilator-associated pneumonia, acute pneumonia, and chronic pulmonary infections. The emergence and spread of antibiotic-resistant strains represent a major public health concern, particularly in...
Bárbara Rafaela Ferreira Aio, Gustavo Aparecido da Cunha, L. C. Malaquias et al.· Microbiology Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.